Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
21 March 2024 - 7:30AM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
today announced that the Company will participate in the H.C.
Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual
Conference.
- Thursday, March 28th, Remy Durand, Ph.D., Chief Business
Officer at Alpine, will participate in a fireside chat at 3:00 pm
ET/12:00 pm PT and the Company will host investor meetings the same
day.
Live webcasts of the fireside chats will be available in the
investor relations section of the Company’s website at
https://ir.alpineimmunesciences.com/events and a replay will be
available on the Company's website for 90 days following the
event.
About Alpine Immune
Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
www.alpineimmunesciences.com visit. Follow @AlpineImmuneSci on X
and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240320830092/en/
Media and Investor
Relations: ir@alpineimmunesciences.com
media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Apr 2023 to Apr 2024